中金发表报告指，信达生物(01801.HK) 2024年收入94.2亿元人民币(下同)，按年升51.8%，超该行预期，主要由于授权费用收入超预期。产品销售收入82.3亿元，按年增43.6%，符合该行预期。净亏损9,463万元，实现non-IFRS净利润3.31亿元，超该行预期，主要由于收入增长及营运效率提高。
中金基本维持信达生物2025年净利润预测4.72亿元不变，考虑到公司创新产品不断兑现，上调2026年净利润预测7.3%至12.9亿元。考虑到创新药估值中枢上行，维持对其“跑赢行业”评级，上调目标
价22.5%至58.8港元。(ha/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-02 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.